Study site

Berlin 13353

3 studies enrolling now · 11 studies all time

What they study most

Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH), Alpha1-proteinase Inhibitor Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Emphysema, HAE With Normal C1 Esterase Inhibitor, Hemophilia A, Hereditary Angioedema, Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1

Studies at this site

• Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency — Recruiting now
• Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE — Recruiting now
• Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema — Enrolling by invitation
• Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE — Running, not enrolling
• Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema — Completed
• Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema — Completed
• Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II — Completed
• A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route — Completed
• A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema — Completed
• An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A — Completed
• Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency — Completed